Table 1.
Cumulative incidence rate of malignancy within the first 10 years after diagnosis in 217 patients with psoriatic arthritis (PsA) compared to 434 subjects without PsA
| Malignancy Site* | Number of events after incidence in PsA/index in non-PsA |
Cumulative incidence at 10 years for PsA patients (± SE) |
Cumulative incidence at 10 years for non-PsA subjects (± SE) |
Hazard ratio (95% confidence interval) |
|---|---|---|---|---|
| Any malignancy (including NMSC) |
43/70 | 12.3 ± 2.5 | 8.6 ± 1.5 | 1.41 (0.96, 2.07) |
| Any malignancy (excluding NMSC) |
30/45 | 9.7 ± 2.2 | 5.1 ± 1.2 | 1.64 (1.03, 2.61) |
| Solid | 24/39 | 8.0 ± 2.1 | 4.2 ± 1.1 | 1.48 (0.89, 2.48) |
| Hematologic | 5/6 | 1.6 ± 0.9 | 0.8 ± 0.5 | 2.48 (0.75, 8.13) |
| NMSC | 22/36 | 4.2 ± 1.5 | 4.4 ± 1.1 | 1.23 (0.72, 2.09) |
| Breast (female only) |
8/6 | 7.3 ± 3.2 | 2.2 ± 1.3 | 3.59 (1.22, 10.61) |
| Prostate (male only) |
9/11 | 5.5 ± 2.2 | 1.8 ± 0.9 | 1.83 (0.75, 4.46) |
No malignancies were observed in these sites: liver, other thorax, bone, ovary, other genitourinary, ophthalmologic, multiple myeloma, myeloproliferative syndrome, myelodysplastic syndrome. Comparisons were not performed for the following sites with fewer than 5 malignancies per cohort (number of events after incidence in PsA/ index in non-PsA): head/neck (2/3), gastric (1/1), pancreatic (1/1), colon/rectal (1/3), other digestive (0/4), lung (2/9), soft tissue (0/1), melanoma (1/1), DCIS (1/1), Other gynecological (1/2), kidney (0/1), bladder (0/1), central nervous system (2/1), lymphoma (2/4), leukemia (4/1) and other (1/1).
Abbreviations: NMSC=non-melanoma skin cancer; DCIS=ductal carcinoma in situ; SE=standard error